Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Experiences with telemedicine for HIV care in two federally qualified health centers in Los Angeles: a qualitative study.
Journal: BMC health services research
Published: September 26, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
Journal: Open forum infectious diseases
Published: October 27, 2021
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
Journal: AIDS (London, England)
Published: October 15, 2021
Nitric Oxide Production in the Striatum and Cerebellum of a Rat Model of Preterm Global Perinatal Asphyxia.
Journal: Neurotoxicity research
Published: September 13, 2016
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Journal: The Lancet. Infectious diseases
Published: May 14, 2015
Showing 1-5 of 5
Last Updated: 09/26/2026